| Sep 11 |
BriaCell stock rockets 150% on positive Phase 2 data for Bria-IMT
|
| Sep 11 |
BriaCell Reports Longer Overall Survival Rate in Phase 2 Breast Cancer Study
|
| Sep 11 |
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
|
| Sep 10 |
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
|
| Sep 9 |
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
| Jul 18 |
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
|
| Jun 3 |
BriaCell Presents Clinical Efficacy Data at ASCO 2024
|
| May 30 |
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
|
| May 28 |
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
|
| May 28 |
BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment
|
